Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx Pharmaceutical

globenewswire.com

Levi & Korsinsky, LLP: Section 10(b) and Rule 10b-5 Claims Filed Against Ultragenyx Pharmaceutical NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

YOU MAY BE AFFECTED IF YOU:

Find out if you qualify or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.

The Federal Securities Law Framework

Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 prohibit making untrue statements of material facts or omitting material facts necessary to make statements not misleading. The action contends that Ultragenyx and certain officers violated these provisions through allegedly false and misleading statements about the Company's Phase III clinical studies.

Claims Pleaded in the Complaint

Procedural Posture and Class Certification

As pleaded, the action was filed in the United States District Court, Northern District of California on February 4, 2026. Plaintiffs allege that the market for RARE common stock was efficient and that the fraud-on-the-market doctrine establishes a presumption of reliance for class members.

"The PSLRA provides important protections for investors harmed by alleged securities violations," said Joseph E. Levi, Esq. "The extensive documentation of management's statements during earnings calls supports detailed examination of what executives knew when making representations to investors."

Learn more about this lawsuit or contact our attorneys at (212) 363-7500.

WHY LEVI & KORSINSKY

Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors across the country. Motions for lead plaintiff must be filed with the Court by April 6, 2026.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

(212) 363-7500

jlevi@levikorsinsky.com

www.zlk.com